Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study
Purpose - - To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. - - Patients and Methods - - Between 1996 and 2003, 933 patients (median age, 47 years; range 15 to 60 years) with untr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 23, 2011
|
| In: |
Journal of clinical oncology
Year: 2011, Volume: 29, Issue: 19, Pages: 2696-2702 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2010.33.7303 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2010.33.7303 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2010.33.7303 
|
| Author Notes: | Markus Schaich, Christoph Röllig, Silke Soucek, Michael Kramer, Christian Thiede, Brigitte Mohr, Uta Oelschlaegel, Norbert Schmitz, Reingard Stuhlmann, Hannes Wandt, Kerstin Schäfer-Eckart, Walter Aulitzky, Martin Kaufmann, Heinrich Bodenstein, Joachim Tischler, Anthony Ho, Alwin Krämer, Martin Bornhäuser, Johannes Schetelig, and Gerhard Ehninger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1818221233 | ||
| 003 | DE-627 | ||
| 005 | 20230710112030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221007s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2010.33.7303 |2 doi | |
| 035 | |a (DE-627)1818221233 | ||
| 035 | |a (DE-599)KXP1818221233 | ||
| 035 | |a (OCoLC)1389779258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schaich, Markus |e VerfasserIn |0 (DE-588)1111909857 |0 (DE-627)865957487 |0 (DE-576)476317320 |4 aut | |
| 245 | 1 | 0 | |a Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia |b results of patients enrolled onto the prospective randomized AML96 study |c Markus Schaich, Christoph Röllig, Silke Soucek, Michael Kramer, Christian Thiede, Brigitte Mohr, Uta Oelschlaegel, Norbert Schmitz, Reingard Stuhlmann, Hannes Wandt, Kerstin Schäfer-Eckart, Walter Aulitzky, Martin Kaufmann, Heinrich Bodenstein, Joachim Tischler, Anthony Ho, Alwin Krämer, Martin Bornhäuser, Johannes Schetelig, and Gerhard Ehninger |
| 246 | 3 | 3 | |a Cytarabine dose of 36 g/m 2 compared with 12 g/m 2 within first consolidation in acute myeloid leukemia |
| 264 | 1 | |c May 23, 2011 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist die Zahl 2 jeweils hochgestellt | ||
| 500 | |a Gesehen am 07.10.2022 | ||
| 520 | |a Purpose - - To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. - - Patients and Methods - - Between 1996 and 2003, 933 patients (median age, 47 years; range 15 to 60 years) with untreated AML were randomly assigned at diagnosis to receive cytarabine within the first consolidation therapy at either a intermediate-dose of 12 g/m2 (I-MAC) or a high-dose of 36 g/m2 (H-MAC) combined with mitoxantrone. Autologous hematopoietic stem-cell transplantation or intermediate-dose cytarabine (10 g/m2) were offered as second consolidation. Patients with a matched donor could receive an allogeneic transplantation in a risk-adapted manner. - - Results - - After double induction therapy including intermediate-dose cytarabine (10 g/m2), mitoxantrone, etoposide, and amsacrine, complete remission was achieved in 66% of patients. In the primary efficacy analysis population, a consolidation with either I-MAC or H-MAC did not result in significant differences in the 5-year overall (30% v 33%; P = .77) or disease-free survival (37% v 38%; P = .86) according to the intention-to-treat analysis. Besides a prolongation of neutropenia and higher transfusion demands in the H-MAC arm, rates of serious adverse events were comparable in the two groups. - - Conclusion - - In young adults with AML receiving intermediate-dose cytarabine induction, intensification of the cytarabine dose beyond 12 g/m2 within first consolidation did not improve treatment outcome. | ||
| 700 | 1 | |a Röllig, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soucek, Silke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kramer, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thiede, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mohr, Brigitte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oelschlaegel, Uta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stuhlmann, Reingard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wandt, Hannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aulitzky, Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaufmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bodenstein, Heinrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tischler, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schetelig, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ehninger, Gerhard |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 29(2011), 19, Seite 2696-2702 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia results of patients enrolled onto the prospective randomized AML96 study |
| 773 | 1 | 8 | |g volume:29 |g year:2011 |g number:19 |g pages:2696-2702 |g extent:7 |a Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia results of patients enrolled onto the prospective randomized AML96 study |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2010.33.7303 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2010.33.7303 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221007 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 50000 |e 50000PK1067780025 |k 0/50000/ |p 17 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 16 | ||
| 999 | |a KXP-PPN1818221233 |e 4195114357 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Markus","display":"Schaich, Markus","family":"Schaich"},{"family":"Röllig","given":"Christoph","role":"aut","display":"Röllig, Christoph"},{"display":"Soucek, Silke","given":"Silke","role":"aut","family":"Soucek"},{"role":"aut","given":"Michael","display":"Kramer, Michael","family":"Kramer"},{"family":"Thiede","given":"Christian","role":"aut","display":"Thiede, Christian"},{"family":"Mohr","given":"Brigitte","role":"aut","display":"Mohr, Brigitte"},{"role":"aut","given":"Uta","display":"Oelschlaegel, Uta","family":"Oelschlaegel"},{"role":"aut","given":"Norbert","display":"Schmitz, Norbert","family":"Schmitz"},{"role":"aut","given":"Reingard","display":"Stuhlmann, Reingard","family":"Stuhlmann"},{"family":"Wandt","role":"aut","given":"Hannes","display":"Wandt, Hannes"},{"display":"Schäfer-Eckart, Kerstin","given":"Kerstin","role":"aut","family":"Schäfer-Eckart"},{"family":"Aulitzky","given":"Walter","role":"aut","display":"Aulitzky, Walter"},{"display":"Kaufmann, Martin","given":"Martin","role":"aut","family":"Kaufmann"},{"display":"Bodenstein, Heinrich","given":"Heinrich","role":"aut","family":"Bodenstein"},{"family":"Tischler","display":"Tischler, Joachim","role":"aut","given":"Joachim"},{"family":"Ho","display":"Ho, Anthony Dick","given":"Anthony Dick","role":"aut"},{"family":"Krämer","given":"Alwin","role":"aut","display":"Krämer, Alwin"},{"family":"Bornhäuser","display":"Bornhäuser, Martin","role":"aut","given":"Martin"},{"given":"Johannes","role":"aut","display":"Schetelig, Johannes","family":"Schetelig"},{"family":"Ehninger","given":"Gerhard","role":"aut","display":"Ehninger, Gerhard"}],"name":{"displayForm":["Markus Schaich, Christoph Röllig, Silke Soucek, Michael Kramer, Christian Thiede, Brigitte Mohr, Uta Oelschlaegel, Norbert Schmitz, Reingard Stuhlmann, Hannes Wandt, Kerstin Schäfer-Eckart, Walter Aulitzky, Martin Kaufmann, Heinrich Bodenstein, Joachim Tischler, Anthony Ho, Alwin Krämer, Martin Bornhäuser, Johannes Schetelig, and Gerhard Ehninger"]},"id":{"eki":["1818221233"],"doi":["10.1200/JCO.2010.33.7303"]},"physDesc":[{"extent":"7 S."}],"note":["Im Titel ist die Zahl 2 jeweils hochgestellt","Gesehen am 07.10.2022"],"relHost":[{"pubHistory":["1.1983 -"],"part":{"volume":"29","year":"2011","text":"29(2011), 19, Seite 2696-2702","issue":"19","pages":"2696-2702","extent":"7"},"language":["eng"],"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"recId":"313116962","origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"disp":"Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia results of patients enrolled onto the prospective randomized AML96 studyJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}]}],"titleAlt":[{"title":"Cytarabine dose of 36 g/m 2 compared with 12 g/m 2 within first consolidation in acute myeloid leukemia"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1818221233","origin":[{"dateIssuedDisp":"May 23, 2011","dateIssuedKey":"2011"}],"title":[{"title_sort":"Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia","title":"Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia","subtitle":"results of patients enrolled onto the prospective randomized AML96 study"}],"language":["eng"]} | ||
| SRT | |a SCHAICHMARCYTARABINE2320 | ||